{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:12:34Z","timestamp":1789729954576,"version":"4.0.1"},"reference-count":62,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Outcomes for patients with hemophilia have improved dramatically over the past 50 years. With the increased availability of safe clotting factor concentrates, the primary focus in clinical management is now the prevention of long-term complications, most notably the debilitating hemophilic arthropathy that is associated with severe disease. This article reviews evidence-based approaches for managing both children and adults with hemophilia. Definitive evidence of improved clinical results from primary prophylaxis started in young patients with severe hemophilia A and a minimal bleeding history is presented. Furthermore, recent studies showing benefits for initiating prophylaxis in older adolescents and adults with established joint disease are examined. Inhibitors to factor VIII are the most problematic complication of factor replacement therapy. Patient-specific and treatment-related factors that contribute to the risk of inhibitor formation are discussed and controversies and clinical evidence related to approaches for tolerance induction are reviewed.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.261","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["The hemophilias and their clinical management"],"prefix":"10.1182","volume":"2013","author":[{"given":"Neil","family":"Josephson","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, WA; and"},{"name":"Hemophilia Care Program, Puget Sound Blood Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111705074538600_B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"2019111705074538600_B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"issue":"6","key":"2019111705074538600_B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111705074538600_B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111705074538600_B5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2007.06703.x","article-title":"The risk associated with indwelling catheters in children with haemophilia","volume":"138","author":"Ljung","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111705074538600_B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2516.2011.02554.x","article-title":"Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres","volume":"18","author":"Ragni","year":"2012","journal-title":"Haemophilia"},{"issue":"6","key":"2019111705074538600_B7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111705074538600_B8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2516.2008.01664.x","article-title":"Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A","volume":"14","author":"Risebrough","year":"2008","journal-title":"Haemophilia"},{"issue":"12","key":"2019111705074538600_B9","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/jth.12025","article-title":"Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada","volume":"10","author":"Kraft","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111705074538600_B10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V99.7.2337","article-title":"The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia","volume":"99","author":"Fischer","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111705074538600_B11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111705074538600_B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111705074538600_B13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1365-2516.2002.00694.x","article-title":"Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen","volume":"8","author":"Fischer","year":"2002","journal-title":"Haemophilia"},{"issue":"1","key":"2019111705074538600_B14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"key":"2019111705074538600_B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2516.2010.02301.x","article-title":"Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications","volume":"16","author":"Santagostino","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"2019111705074538600_B16","first-page":"165","article-title":"Prophylaxis in haemophilia should be life-long","volume":"10","author":"Makris","year":"2012","journal-title":"Blood Transfus"},{"issue":"1","key":"2019111705074538600_B17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2141.2005.05546.x","article-title":"Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands","volume":"130","author":"van Dijk","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111705074538600_B18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111705074538600_B19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111705074538600_B20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"key":"2019111705074538600_B21","first-page":"503","article-title":"Prophylaxis versus on-demand therapy through economic report (P.O.T.T.E.R.) study","volume":"7","author":"Tagliaferri","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111705074538600_B22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2141.2010.08469.x","article-title":"Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States","volume":"152","author":"Witmer","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111705074538600_B23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood"},{"key":"2019111705074538600_B24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","article-title":"Personalized prophylaxis","volume":"18","author":"Collins","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"2019111705074538600_B25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"den Uijl","year":"2009","journal-title":"Haemophilia"},{"issue":"4","key":"2019111705074538600_B26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/hae.12119","article-title":"Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A","volume":"19","author":"Sood","year":"2013","journal-title":"Haemophilia"},{"key":"2019111705074538600_B27","first-page":"1","article-title":"Outcome in moderate haemophilia","author":"Den Uijl","year":"2012","journal-title":"Blood Transfus"},{"key":"2019111705074538600_B28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2007.01606.x","article-title":"Desmopressin for the treatment of haemophilia","volume":"14","author":"Castaman","year":"2008","journal-title":"Haemophilia"},{"issue":"7","key":"2019111705074538600_B29","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2019111705074538600_B30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2516.2011.02572.x","article-title":"DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype","volume":"18","author":"Seary","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"2019111705074538600_B31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1160\/TH12-06-0383","article-title":"Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A","volume":"109","author":"Stoof","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111705074538600_B32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/hae.12173","article-title":"Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild haemophilia A","volume":"19","author":"Nance","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"2019111705074538600_B33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs","volume":"339","author":"Mannucci","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111705074538600_B34","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1538-7836.2007.02755.x","article-title":"Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A","volume":"5","author":"Hvas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2019111705074538600_B35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/jcp.33.Suppl_14.50","article-title":"Inhibitors of fibrinolysis in the treatment of haemophilia","volume":"14","author":"Rizza","year":"1980","journal-title":"J Clin Pathol Suppl (R Coll Pathol)"},{"issue":"3","key":"2019111705074538600_B36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111705074538600_B37","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111705074538600_B38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"issue":"20","key":"2019111705074538600_B39","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111705074538600_B40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1538-7836.2007.02595.x","article-title":"Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A","volume":"5","author":"Gouw","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111705074538600_B41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Treatment related factors and inhibitor development in children with severe haemophilia A","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"key":"2019111705074538600_B42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1538-7836.2011.04349.x","article-title":"Immune tolerance induction in haemophilia: evidence and the way forward","volume":"9","author":"Di Michele","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111705074538600_B43","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111705074538600_B44","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111705074538600_B45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"issue":"102","key":"2019111705074538600_B46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2516.2008.01923.x","article-title":"Inhibitor development: patient-determined risk factors","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"8","key":"2019111705074538600_B47","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2012-06-434803","article-title":"The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort","volume":"121","author":"Astermark","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111705074538600_B48","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111705074538600_B49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"3","key":"2019111705074538600_B50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/hae.12149","article-title":"The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters","volume":"19","author":"Kessler","year":"2013","journal-title":"Haemophilia"},{"key":"2019111705074538600_B51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2012.02794.x","article-title":"The role of natural VWF\/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade","volume":"18","author":"Mannucci","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"2019111705074538600_B52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2010.08263.x","article-title":"Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches","volume":"150","author":"Coppola","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111705074538600_B53","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111705074538600_B54","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"2019111705074538600_B55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2516.2007.01579.x","article-title":"VWF\/FVIII concentrates in high-risk immunotolerance: the RESIST study","volume":"13","author":"Gringeri","year":"2007","journal-title":"Haemophilia"},{"issue":"2","key":"2019111705074538600_B56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111705074538600_B57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"issue":"9","key":"2019111705074538600_B58","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"18","key":"2019111705074538600_B59","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"key":"2019111705074538600_B60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/asheducation-2013.1.37","article-title":"Long-lasting recombinant factor VIII proteins for hemophilia A","volume":"2013","author":"Shapiro","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111705074538600_B61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/asheducation-2013.1.44","article-title":"The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders","volume":"2013","author":"Ragni","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"2019111705074538600_B62","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/261\/1249622\/bep00113000261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/261\/1249622\/bep00113000261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:08:21Z","timestamp":1573985301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/261\/20769\/The-hemophilias-and-their-clinical-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.261","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}